Neomycin

Generic Name: Neomycin

Brand Names: Casporyn HC, Cortisporin, Cortisporin-TC, Dioptrol, Diosporin, Diphen, Maxitrol, Neo-polycin, Neo-polycin HC, Neo-synalar, Neosporin Ointment, Neosporin Plus Maximum Strength, Neosporin Plus Maximum Strength Cream, Neosporin Solution, Procomycin, Statrol, Triple Antibiotic, Viaderm Kc

Drug Type: Small Molecule

Chemical Formula: -

CAS Number: 1404-04-2

Unique Ingredient Identifier: I16QD7X297

Background: Neomycin is a broad-spectrum aminoglycoside antibiotic drug that is derived from the metabolic products of Streptomyces fradiae. Neomycin is a complex comprised of three components, neomycin A, B, and C. Neomycin B, also known as framycetin, is the most active component of the complex and neomycin C is the isomer of neomycin B, making these two stereoisomers...

Indication: Oral neomycin sulfate is indicated as an adjunctive therapy in hepatic coma (portal-system encephalopathy) by reducing ammonia-forming bacteria in the intestinal tract. It is strongly recommended that oral neomycin is only used in infections that are proven or strongly suspected to be caused by susceptible bacteria to reduce the risk of the development of dr...

Associated Conditions: Allergic Contact Dermatitis, Allergic Skin Reaction, Atopic Dermatitis, Atopic Dermatitis (AD) of the external ear canal, Bacterial diarrhoea, Burns, Carbuncle, Contact Dermatitis, Cradle Cap, Dermatitis, Diarrhea, Discoid Lupus Erythematosus (DLE), Ear infection bacterial, Ear infection bacterial caused by susceptible bacteria, Gastrointestinal Tract Infections, Hepatic coma, Hidradenitis Suppurativa (HS), Hot Water Burns (Scalds), Impetigo, Impetigo contagious, Infantile Eczema, Infected skin ulcer, Infection of the outer ear caused by susceptible bacteria, Infectious diarrhea, Inflammatory Reaction caused by Acne, Intertrigo, Itching caused by Infection, Lichen Planus (LP), Localized Infection caused by susceptible bacteria, Nail infection, Neurodermatitis, Otitis Externa, Postoperative Wound Infection, Psoriasis Vulgaris (Plaque Psoriasis), Pustular Dermatosis, Pustular acne, Radiodermatitis, Secondarily Infected Eczema, Secondary Bacterial Infection, Skin Burn, Skin Infections, Skin Irritation, Skin Ulcer, Solar erythema, Wound Infections, Abrasions, Bacterial skin infections, Blistering caused by Staphylococcus, Erythematous eruptions, Intertriginous erythema of the anogenital, Ocular bacterial infections caused by susceptible bacteria, Resistant to other corticosteroids Dermatosis, Susceptible Bacterial Infections

Associated Therapies: -

Clinical Trials

Effect of Neomycin on the Pharmacokinetics of Regorafenib

Phase 1

Completed

Conditions: Neoplasms

Interventions: Drug: Regorafenib (Stivarga, BAY73-4506)
Drug: Neomycin

First Posted Date: 2013-12-05

Last Posted Date: 2015-08-13

Lead Sponsor: Bayer

Target Recruit Count: 27

Registration Number: NCT02001909

Role of Methane in Glycemic Control

Early Phase 1

Completed

Conditions: Diabetes
Obesity

Interventions: Drug: Neomycin
Drug: Rifaximin

First Posted Date: 2012-07-11

Last Posted Date: 2019-05-02

Lead Sponsor: Cedars-Sinai Medical Center

Target Recruit Count: 11

Registration Number: NCT01638429

Locations: 🇺🇸
Cedars-Sinai Medical Center, Los Angeles, California, United States

Comparison Between Erythromycin and Neomycin Treatment of Hepatic Encephalopathy

Not Applicable

Conditions: Hepatic Encephalopathy
Hypertension, Portal
Liver Cirrhosis

Interventions: Drug: Erythromycin
Drug: Neomycin

First Posted Date: 2010-04-02

Last Posted Date: 2010-04-28

Lead Sponsor: UPECLIN HC FM Botucatu Unesp

Target Recruit Count: 20

Registration Number: NCT01097811

Locations: 🇧🇷
Faculdade de Medicina de Botucatu - Universidade Estadual Paulista, Botucatu, São Paulo, Brazil

Neomycin and Rifaximin Plus Neomycin in Treating Methane Positive Constipation Predominant Irritable Bowel Syndrome

Not Applicable

Completed

Conditions: Constipation-predominant Irritable Bowel Syndrome

Interventions: Drug: Neomycin
Drug: Placebo
Drug: Rifaximin

First Posted Date: 2009-07-24

Last Posted Date: 2015-08-10

Lead Sponsor: Mark Pimentel, MD

Target Recruit Count: 37

Registration Number: NCT00945334

Locations: 🇺🇸
Cedars-Sinai Medical Center, Los Angeles, California, United States
🇺🇸
Georgia Health Sciences University, Augusta, Georgia, United States